Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) and maintained a $60 price target on the stock.
May 08, 2024 | 9:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham maintains a Buy rating and a $60 price target on Ionis Pharmaceuticals.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Ionis Pharmaceuticals' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100